CollPlant (CLGN) VP details option and restricted share unit holdings

Rhea-AI Filing Summary

CollPlant Biotechnologies Ltd VP of Product Development Jasmine Seror has filed an initial Form 3 outlining her equity-based holdings in the company. The filing lists several option grants to purchase Ordinary Shares and restricted share unit awards, all reported as directly owned.

Seror holds options over 4,000 and 1,000 Ordinary Shares with an exercise price of $4.0200 per share, and additional options over 5,000, 6,000 and 3,600 Ordinary Shares at $6.3900 per share, with expirations between 2027 and 2032. She also holds 12,000 restricted share units, of which 5,250 are vested and 6,750 vest in nine equal quarterly installments from June 8, 2026 to June 8, 2028, and a further 45,000 restricted shares vesting over three years, with 33% vesting on November 25, 2026 and the remaining 67% in eight equal quarterly installments. One option grant is described as fully vested and exercisable.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Seror Jasmine

(Last) (First) (Middle)

C/O COLLPLANT BIOTECHNOLOGIES LTD.

4 OPPENHEIMER ST, WEIZMANN SCIENCE PARK

(Street)

REHOVOT 7670104

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
CollPlant Biotechnologies Ltd [ CLGN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP Product Development

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Restricted Share Units	12,000(2)	D
Restricted Share Units	45,000(3)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Ordinary Shares(1)(4)	12/26/2018	12/26/2027	Ordinary Shares	4,000(4)	$4.02	D
Options to Purchase Ordinary Shares(1)(4)	05/18/2016	05/18/2028	Ordinary Shares	1,000(4)	$4.02	D
Options to Purchase Ordinary Shares(1)(4)	01/13/2022	01/13/2031	Ordinary Shares	5,000(4)	$6.39	D
Options to Purchase Ordinary Shares(1)(4)	01/27/2023	01/27/2032	Ordinary Shares	6,000(4)	$6.39	D
Options to Purchase Ordinary Shares(1)(4)	05/26/2021	05/26/2030	Ordinary Shares	3,600(4)	$6.39	D

Explanation of Responses:

1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's Share Ownership and Option Plan (2010) or 2024 Share Award Plan must be registered in the name of a trustee.

2. Of the restricted share units reported herein, 5,250 units are vested, and the remaining 6,750 units vest in nine equal quarterly installments beginning June 8, 2026 and ending June 8, 2028, subject to the Reporting Person's continued service to the Issuer as of such vesting date.

3. The restricted shares shall vest over a period of 3 years: 33% shall vest on November 25, 2026, and the remaining 67% shall vest in eight equal quarterly installments thereafter.

4. Fully vested and exercisable.

	/s/ Jasmine Seror	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What insider ownership does CLGN VP Jasmine Seror report on Form 3?

Jasmine Seror reports a mix of stock options and restricted equity in CollPlant Biotechnologies. She lists five option grants over Ordinary Shares plus 12,000 restricted share units and 45,000 restricted shares, all as directly owned equity-based compensation positions.

How many CollPlant (CLGN) stock options does Jasmine Seror hold and at what exercise prices?

Jasmine Seror holds options over 4,000 and 1,000 Ordinary Shares at an exercise price of $4.0200, plus options over 5,000, 6,000 and 3,600 shares at $6.3900. These option grants have expiration dates ranging from 2027 through 2032.

How are Jasmine Seror’s 12,000 CLGN restricted share units scheduled to vest?

Of the 12,000 restricted share units, 5,250 are already vested and 6,750 remain unvested. The remaining 6,750 units vest in nine equal quarterly installments beginning June 8, 2026 and ending June 8, 2028, contingent on continued service.

What is the vesting schedule for the 45,000 CollPlant Biotechnologies restricted shares?

The 45,000 restricted shares vest over three years. According to the disclosure, 33% vest on November 25, 2026, and the remaining 67% vest in eight equal quarterly installments thereafter, subject to Jasmine Seror’s continued service to CollPlant.

Are any of Jasmine Seror’s CollPlant stock options already fully vested and exercisable?

Yes, at least one option grant is described as fully vested and exercisable. The filing notes that a specific option award is “fully vested and exercisable,” meaning all underlying option shares are currently available for exercise under its stated terms.

How does Israeli Section 102 affect Jasmine Seror’s CLGN equity awards?

To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, equity issued under CollPlant’s 2010 or 2024 share plans must be registered in a trustee’s name. This structure is used for Jasmine Seror’s awards to obtain those Israeli tax advantages.